INS and obesity disorder: Glucagon-like peptide 1 receptor agonists (GLP-1RA), used for the treatment of T2D and obesity, demonstrated potential efficacy in clinical trials also in T1Ds when adjunct to insulin; a recent meta-analysis confirmed that GLP-1RA improve glycemic control, reduce severe hypoglycemia, body weight, and insulin requirements [28].